Navigation Links
Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed

DUSSELDORF, Germany, April 2 /PRNewswire-FirstCall/ -- In the first quarter of 2009 (December 2008 to February 2009) Gerresheimer AG maintained its total sales figure of EUR237.3m (Q1 2008: EUR239.1m) almost at the prior year level despite the difficult overall situation in the world economy. In the core business, however, sales by the MDAX company actually rose by 2.8 % to EUR228.7m

The operating result (adjusted EBITDA) fell in comparison with the prior year period from EUR43.0m to EUR38.3m. This is attributable to a slightly negative result in the segment of Technical Plastics and temporary capacity adjustments. The operating margin (adjusted EBITDA margin) of Gerresheimer AG came to 16.1 % for this period (Q1 2008: 18.0%), although in the core business it reached a solid 17.1 %. Adjusted net income for the Group in the first quarter of 2009 totaled EUR6.4m (Q1 2008: EUR9.9m).

Despite the difficult overall economic environment Gerres­heimer achieved profitable growth in its core markets in the first quarter. It is advantageous that the global pharma markets continue to be robust. "We still assume that we will achieve sales growth of 6% to 7% in the financial year 2009 with an adjusted EBITDA margin of 19.0% to 19.2% in our core business," says Dr. Axel Herberg, CEO of Gerres­heimer AG.

Further growth in the core markets of pharma & life science

Sales by the core businesses increased again in the first quarter of 2009. This development highlights the strategic importance of Gerresheimer's focus on the markets of pharma & life science. In the first quarter 2009, 78% of Gerresheimer's total sales were attribut­able to this market segment. In contrast, sales for the Technical Plastics business, which is up for sale, halved in the first quarter to EUR8.6m.

In the first quarter of 2009 some customers in the pharma & life science industry reduced their inventories as expected. In addition, demand for high-quality cosmetics was substantially lower. In contrast, the Tubular Glass and Plastic Systems Divisions further increased their sales in the months of December 2008 to February 2009. The busi­ness in RTF(R) syringe systems, inhalation devices and insulin pens again experienced a high level of demand. Thanks to the launch of the third RTF(R) syringe line and further investments in expansion of production for drug delivery systems Gerresheimer will generate further growth.

Gerresheimer consistently continues its growth strategy

Gerresheimer AG stands by its objective of further profitable growth in the financial year 2009. Gerresheimer will continue in 2009 to invest extensively in new product lines and capacity expansion. We are therefore fully on plan in implementing our growth strategy. As a leading partner for companies in the pharma & life science indus­try, Gerres­heimer expects further increasing worldwide demand for safe and user-friendly medical treatment.

About Gerresheimer

Gerresheimer employs 10,200 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

    Group Key Figures (IFRS; End of Q1 2009: February 28,
    Q1 2008: February 29; Financial Year end November 30)

    in EUR million     Q1 2009 Q1 2008  Change % FY 2008
    Net sales           237.3   239.1    -0.8  1.060.1

    thereof core
    net sales           228.7   222.5    +2.8    997.1
    Adjusted EBITDA[1]   38.3    43.0   -10.9    206.4

    in % of net sales    16.1    18.0             19.5
    thereof core
    adjusted EBITDA      39.0    N/A[2]           N/A[2]

    in % of net sales    17.1    N/A[2]           N/A[2]
    Adjusted EBITA       19.8    25.5   -22.4    135.6

    in % of net sales     8.3    10.7             12.8
    Profit from
    operations (EBIT)     9.2    14.9   -38.3     61.0
    Net income           -1.1     2.5              4.5
    Adjusted net
    income[3]             6.4     9.9   -35.4     61.4
    Earnings per share
    in EUR              -0.05    0.06             0.02
    Adjusted earnings    0.18    0.29   -37.9     1.83
    per share[4] in EUR


[1] Adjusted EBITDA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

[2] The prior year adjusted EBITDA of the Technical Plastic Systems business is not available as the separation was carried out in the course of the financial year and is therefore included in the Plastic Systems segment

[3] Adjusted net income: Consolidated profit before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects

    [4] Adjusted net income after minorities divided by 31.4m shares

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax +49-211-6181-241

    Contact Investor Relations
    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Gerresheimer Continues Expansion Course
2. Blackstone Sells Gerresheimer Stake
3. Standard & Poors Raises Gerresheimer Rating to BB+
4. Gerresheimer Starts the Year Successfully in 2008
5. Gerhard Schulze New Chairman of the Supervisory Board of Gerresheimer AG
6. Gerresheimer Finalises Purchase of Spanish Company EDP
7. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
8. Linnartz New Head of Investor Relations of Gerresheimer
9. Growth Trend for Gerresheimer Continues Unabated - Debt Reduction
10. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
11. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology: